Why Chemomab Therapeutics Ltd. (CMMB) Stock Leapt More Than 3.98% Today? Here Is The Reason
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company specializing in the commercialization of innovative therapeutics for fibrosis-related diseases with rising unmet demand, announced enlistment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). At last check in current trading, shares of Chemomab Therapeutics Ltd. (CMMB) were up 3.98% […]
